Cargando…

Functional imaging of pharmacological action of SGLT2 inhibitor ipragliflozin via PET imaging using (11)C‐MDG

Sodium‐dependent glucose cotransporter 2 (SGLT2) is a pharmacological target of type 2 diabetes mellitus. The aim of this study was to noninvasively visualize the pharmacological action of a selective SGLT2 inhibitor ipragliflozin in the kidney using positron emission tomography (PET) imaging with (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mitsuoka, Keisuke, Hayashizaki, Yuka, Murakami, Yoshihiro, Takasu, Toshiyuki, Yokono, Masanori, Umeda, Nobuhiro, Takakura, Shoji, Noda, Akihiro, Miyoshi, Sosuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242169/ https://www.ncbi.nlm.nih.gov/pubmed/28116097 http://dx.doi.org/10.1002/prp2.244

Ejemplares similares

SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model
por: Tahara, Atsuo, et al.
Publicado: (2019)

Atypical Ketoacidosis and Protracted Hyperglycosuria after Treatment with Ipragliflozin, an SGLT2 Inhibitor
por: Miyauchi, Masaaki, et al.
Publicado: (2017)

The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice
por: Honda, Yasushi, et al.
Publicado: (2016)

Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date
por: Alkabbani, Wajd, et al.
Publicado: (2021)

Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high‐fat diet
por: Takagi, Susumu, et al.
Publicado: (2018)

Glycosuria medicated with ipragliflozin and nifedipine or ipragliflozin and candesartan: a case report
por: Okada, Shuichi, et al.
Publicado: (2014)

Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse
por: Salim, Hotimah Masdan, et al.
Publicado: (2016)

Mod(mdg4) variants repress telomeric retrotransposon HeT-A by blocking subtelomeric enhancers
por: Takeuchi, Chikara, et al.
Publicado: (2022)

Ipragliflozin Ameliorates Endoplasmic Reticulum Stress and Apoptosis through Preventing Ectopic Lipid Deposition in Renal Tubules
por: Hosokawa, Kohshiro, et al.
Publicado: (2019)

Reducing Maternal Mortality and Improving Maternal Health: Bangladesh and MDG 5
por: Koblinsky, Marge, et al.
Publicado: (2008)

Malaria control in South Africa 2000–2010: beyond MDG6
por: Moonasar, Devanand, et al.
Publicado: (2012)

Ipragliflozin Ameliorates Liver Damage in Non-alcoholic Fatty Liver Disease
por: Miyake, Teruki, et al.
Publicado: (2018)

Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway
por: Lee, Ji-Yeon, et al.
Publicado: (2021)

Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD
por: Takahashi, Hirokazu, et al.
Publicado: (2021)

Ipragliflozin/tozinameran: Diabetic ketoacidosis: 2 case reports
Publicado: (2022)

The Difficult Task of Evaluating MDG-4: Monitoring Trends in Child Survival in Africa
por: Garenne, Michel
Publicado: (2015)

Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: An Open-Label Study
por: Ito, Daisuke, et al.
Publicado: (2017)

Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study
por: Fukuda, Tatsuya, et al.
Publicado: (2017)

Repetition of a sisterhood survey at district level in Malawi: the challenge to achieve MDG 5
por: Beltman, Jogchum Jan, et al.
Publicado: (2011)

Global Access to Safe Water: Accounting for Water Quality and the Resulting Impact on MDG Progress
por: Onda, Kyle, et al.
Publicado: (2012)

Effectiveness of Scaling up the ‘Three Pillars’ Approach to Accelerating MDG 4 Progress in Ethiopia
por: Carnell, Mary A., et al.
Publicado: (2014)

The Astronomy of Africa’s Health Systems Literature During the MDG Era: Where Are the Systems Clusters?
por: Phillips, James F, et al.
Publicado: (2015)

Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice
por: Kamezaki, Michitsugu, et al.
Publicado: (2018)

A concise and practical stereoselective synthesis of ipragliflozin L-proline
por: Ma, Shuai, et al.
Publicado: (2017)

Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model
por: Morishita, Asahiro, et al.
Publicado: (2022)

Reply to: “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”
por: van Kleef, Laurens A., et al.
Publicado: (2022)

Model-based Prediction of the Long-term Glucose-Lowering Effects of Ipragliflozin, a Selective Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor, in Patients with Type 2 Diabetes Mellitus
por: Saito, Masako, et al.
Publicado: (2020)

Progress towards the achievement of MDG4 in the Commonwealth of Independent States: uncertain data, clear priorities
por: Cattaneo, Adriano, et al.
Publicado: (2010)

Inequities in utilization of maternal health interventions in Namibia: implications for progress towards MDG 5 targets
por: Zere, Eyob, et al.
Publicado: (2010)

Comprehensive Approach to Improving Maternal Health and Achieving MDG 5: Report from the Mountains of Lesotho
por: Satti, Hind, et al.
Publicado: (2012)

A Successful Failure: Missing the MDG4 Target for Under-Five Mortality in South Africa
por: Byass, Peter, et al.
Publicado: (2015)

MDG-1, a Potential Regulator of PPARα and PPARγ, Ameliorates Dyslipidemia in Mice
por: Wang, Xu, et al.
Publicado: (2017)

Assessment of capital expenditure in achieving sanitation-related MDG targets and the uncertainties of the SDG targets in Algeria
por: Kherbache, Nabil, et al.
Publicado: (2020)

Protein expression pattern of the molecular chaperone Mdg1/ERdj4 during embryonic development
por: Daverkausen-Fischer, Lea, et al.
Publicado: (2020)

Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes
por: Kutoh, Eiji, et al.
Publicado: (2016)

Ipragliflozin Ameliorates Diabetic Nephropathy Associated with Perirenal Adipose Expansion in Mice
por: Okuma, Hideyuki, et al.
Publicado: (2021)

Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes
por: Takahashi, Kiyohiko, et al.
Publicado: (2018)

Ipragliflozin-induced adipose expansion inhibits cuff-induced vascular remodeling in mice
por: Mori, Kentaro, et al.
Publicado: (2019)

Reply to the Letter to the editor “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”
por: Takahashi, Hirokazu, et al.
Publicado: (2022)

Achieving MDG 4 in Sub-Saharan Africa: What Has Contributed to the Accelerated Child Mortality Decline in Ghana?
por: Nakamura, Haruyo, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_qmbashrkj75gafgmeg40befsib